SPINEMarketGroup

Spine Industry News

2026

Boston Scientific Puts $1.5 Billion on MiRus: Why the Spine Market Should Look Beyond TAVR

By

On May 18, Boston Scientific announced a $1.5 billion investment for an approximate 34% equity stake in MiRus LLC, a privately held company based in Georgia and focused on biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Most of the early coverage has naturally focused on the TAVR opportunity. That is where the clearest near-term … [Read more...] about Boston Scientific Puts $1.5 Billion on MiRus: Why the Spine Market Should Look Beyond TAVR

The ASC Opportunity in Spine Will Be Won by Commercial Redesign, Not by Product Alone

By

Spine surgery is moving toward ambulatory surgery centers. That part of the conversation is largely settled. What remains underexamined — especially at the executive level — is the commercial question underneath it: what does a sustainable spine business actually look like when the customer is no longer a large hospital system, but a cost-sensitive, operationally lean surgical … [Read more...] about The ASC Opportunity in Spine Will Be Won by Commercial Redesign, Not by Product Alone

PainTEQ Launches TRAQ™, A Next-Generation Posterior Approach to SI Joint Fusion

By

Built on the proven LINQ® posterior approach, TRAQ™ adds bi-cortical fixation to deliver enhanced sacropelvic stability TAMPA, Fla., May 15, 2026 /PRNewswire/ -- PainTEQ, the pioneer of posterior sacroiliac joint fusion, today announced the U.S. commercial launch of TRAQ™ SI Joint Fusion — the first posterior SI joint implant designed to engage both the sacral … [Read more...] about PainTEQ Launches TRAQ™, A Next-Generation Posterior Approach to SI Joint Fusion

Xtant Medical Reports First Quarter 2026 Financial Results

By

BELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights First Quarter 2026 … [Read more...] about Xtant Medical Reports First Quarter 2026 Financial Results

Autonomous Pedicle Screw Placement: Is Spine Robotics Ready for the Next Step?

By

Robotic guidance, navigation and planning are no longer experimental ideas in spine. They are already part of the market. Different systems follow different strategies, but the underlying message is the same: robotics has become part of how major spine companies want to compete. Still, most of what we call spine robotics today remains robotic assistance. The surgeon is still … [Read more...] about Autonomous Pedicle Screw Placement: Is Spine Robotics Ready for the Next Step?

Medtronic Hits a 52-Week Low: What Is the Market Seeing?

By

In recent weeks, much of the spine market discussion has focused on Globus Medical and the negative market reaction that followed otherwise strong operating results. But Globus is not alone. Medtronic, one of its most direct competitors in spine technology, has also been under pressure. Its stock recently hit a reported 52-week low at $77.15, and by May 11, 2026, was quoted … [Read more...] about Medtronic Hits a 52-Week Low: What Is the Market Seeing?

SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon

By

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American company specialized in complex spine surgery and offering an integrated pre-, intra- and postoperative solution based on 3D planning software, … [Read more...] about SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon

Cervical Fusion Implant Denials: Why Spine Societies Are Pushing Back

By

There are reimbursement disputes that affect only the margins of a market. Others say something more structural about the direction of the industry. The recent statement from leading U.S. spine surgery societies on cervical fusion implant denials belongs to the second category. The issue is not a new device seeking early coverage, nor an experimental technology asking for … [Read more...] about Cervical Fusion Implant Denials: Why Spine Societies Are Pushing Back

Globus Medical: Strong Q1, Weak Stock Reaction — Is the Market Asking for More?

By

Globus Medical’s latest results created an apparent contradiction. The company reported a very strong first quarter, raised its earnings guidance, continued to show the benefits of the NuVasive integration, and reinforced its position as one of the leading players in spine. Yet the stock did not move as many would have expected. In fact, the immediate market reaction was … [Read more...] about Globus Medical: Strong Q1, Weak Stock Reaction — Is the Market Asking for More?

Globus Medical: Stronger in Spine, but Could DePuy Synthes’ Trauma Business Be the Next Big Move?

By

Globus Medical’s first quarter 2026 results confirm something important: the company is no longer just digesting major acquisitions. It is beginning to show the operating logic behind them. The headline figures are strong, but the more relevant point is the quality of the performance. Growth came not only from Nevro, but also from the underlying business, particularly U.S. … [Read more...] about Globus Medical: Stronger in Spine, but Could DePuy Synthes’ Trauma Business Be the Next Big Move?

Globus Medical Reports First Quarter 2026 Results

By

AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: “We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic … [Read more...] about Globus Medical Reports First Quarter 2026 Results

Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants

By

CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced the issuance of its fourth U.S. patent related to Aurora’s proprietary DEXA Technology® platform. The newly issued patent, U.S. Patent No. … [Read more...] about Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants

Carlsmed® Reports First Quarter 2026 Financial

By

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported … [Read more...] about Carlsmed® Reports First Quarter 2026 Financial

SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating

By

DALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News: SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN Code: FR0014005I80 / Ticker: ALSMA), a French-American company specialized in complex spine surgery and offering an integrated pre-, intra- and postoperative solution based on 3D planning software, adaptive implants and … [Read more...] about SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating

Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

By

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All … [Read more...] about Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

Inhaled Corticosteroids and Lumbar Fusion: A New Revision Risk Signal?

By

A new study published in Global Spine Journal, carried out by researchers from Johns Hopkins together with collaborators from the All India Institute of Medical Sciences (AIIMS) in New Delhi, has put an unusual detail on the radar of spine surgeons: the long-term use of inhaled corticosteroids in asthma patients. At first sight, this may sound like a minor point. Inhaled … [Read more...] about Inhaled Corticosteroids and Lumbar Fusion: A New Revision Risk Signal?

Spineway : First-quarter 2026 revenue

By

First-quarter 2026 revenue Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.2 million in the first quarter of 2026. Following strong growth in the fourth quarter of 2025 (+38%), the slowdown observed in the first quarter of 2026 will not undermine the Group’s momentum. It is mainly attributable to delays … [Read more...] about Spineway : First-quarter 2026 revenue

Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion

By

FDA authorization marks critical milestone enabling advancement of next-generation bone regeneration therapy for patients with degenerative spinal diseases FREDERICK, Md., April 30, 2026 /PRNewswire/ -- Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the U.S. Food … [Read more...] about Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion